IgA Nephropathy Therapeutic Market Expected to Witness Robust Growth By 2034, Fueled by Recent FDA Approvals and Clinical Trials Updates | DelveInsight

The IgA Nephropathy (IgAN) treatment market is poised for substantial growth, driven by the introduction of innovative therapies and the increasing prevalence of this chronic kidney disease. Leading IgAN companies, including Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., and Vera Therapeutics, among others, are at the forefront of transforming the IgAN treatment landscape.
DelveInsight's "IgA Nephropathy Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an extensive analysis of IgA nephropathy, including historical and forecasted epidemiology data, current treatment practices, emerging therapies, and market projections across the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan).

The report indicates that the IgA Nephropathy market is anticipated to grow at a robust CAGR of more than 30% from approximately USD 730 million across 7MM in 2024, driven by increasing disease awareness, improved diagnostic capabilities, and the launch of novel therapeutic options targeting specific pathways involved in IgAN pathogenesis.

This market expansion highlights the increasing awareness of IgAN as a major contributor to end-stage renal disease (ESRD) worldwide, as well as the urgent need for effective disease-modifying treatments beyond traditional supportive care. The growth is further fueled by the introduction of innovative therapies, including Povetacicept, Atacicept, Zigakibart, and ULTOMIRIS, among others.

IgA nephropathy, also known as Berger disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli-the tiny filtering units within the kidneys. This abnormal buildup triggers inflammation and progressive damage, impairing the kidneys' ability to filter waste and excess fluid from the blood. Over time, IgA nephropathy can lead to chronic kidney disease or even kidney failure in a significant subset of patients, making it one of the most common causes of glomerulonephritis worldwide.

Download the IgA nephropathy market report to understand which factors are driving the IgA nephropathy therapeutic market @ IgA Nephropathy Market Trends [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

According to DelveInsight's epidemiological analysis, the total diagnosed prevalent population of IgA Nephropathy in the 7MM comprised approximately 415K cases in 2024. Japan accounted for the highest proportion of IgAN diagnosed prevalent cases, with nearly 175K cases. Furthermore, the data reveals a notable gender disparity, with IgA nephropathy showing male predominance in 2024. This epidemiological profile underscores the substantial patient population that could benefit from emerging targeted therapies, thereby driving market growth in the forecast period.

Discover evolving trends in the IgAN patient pool forecasts @ IgAN Epidemiology Analysis [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Recent Developments in IgA Nephropathy Landscape:

*
In April 2025, Novartis announced that the FDA has granted accelerated approval for VANRAFIA (atrasentan), an oral endothelin A receptor antagonist, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression (UPCR greater than or equal to 1.5 g/g). Vanrafia is taken once daily alongside standard supportive care.

*
In April 2025, Vera Therapeutics completed full enrollment in the pivotal ORIGIN Phase III trial evaluating atacicept in patients with IgAN.

*
In May 2025, Otsuka and OPDC announced that the FDA has accepted the Biologics License Application for sibeprenlimab, an investigational antibody targeting APRIL, for the treatment of adults with IgA nephropathy.

Discover recent advancements in the IgA Nephropathy treatment landscape @ IgA Nephropathy Recent Developments [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The DelveInsight report also analyses the current and emerging treatment landscape. Currently, only a few drugs have been approved for IgAN treatment, including VANRAFIA (Atrasentan) and FABHALTA (Iptacopan) by Novartis, FILSPARI (Sparsentan) by Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others.

The IgA nephropathy pipeline is robust, featuring multiple promising candidates in late-stage development that target various pathophysiological mechanisms. Current clinical development programs focus on innovative approaches, including complement pathway inhibition, B-cell modulation, targeted immunosuppression, and novel anti-inflammatory agents. These emerging therapies address the multifaceted nature of IgAN pathogenesis and offer improved efficacy, safety profiles, and quality of life outcomes compared to conventional treatments. The diversification of therapeutic approaches reflects growing understanding of the complex immunological mechanisms underlying IgAN and represents a paradigm shift toward precision medicine in nephrology.

The IgA nephropathy treatment landscape has witnessed significant advancements in recent years, with several breakthrough approvals reshaping clinical practice and further expanding this significant market. In September 2024, Travere Therapeutics achieved a major milestone with the full FDA approval of FILSPARI to slow the decline in kidney function in adults with primary IgA nephropathy. This approval followed an earlier accelerated approval based on proteinuria reduction, with full approval supported by positive long-term data from the PROTECT Study demonstrating sustained clinical benefits. Additionally, FILSPARI received conditional marketing authorization from the European Commission in April 2024 for treating adults with primary IgAN with significant proteinuria.

Discover evolving trends in the IgA Nephropathy treatment landscape @ IgA Nephropathy Therapies Market [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Despite therapeutic advances, significant unmet needs persist in the IgA nephropathy treatment landscape. These include the need for earlier disease detection, biomarkers to predict disease progression and treatment response, and therapies that can reverse existing kidney damage rather than merely slowing disease progression. Moreover, improving access to specialized care and novel therapies remains challenging, particularly in regions with limited healthcare resources. DelveInsight's analysis highlights that addressing these unmet needs will be crucial for optimizing patient outcomes and maximizing the market potential for emerging IgAN therapies.

Looking ahead, the IgA nephropathy market is expected to witness transformative growth. The integration of biomarkers into clinical practice and the development of combination therapeutic strategies targeting multiple pathways simultaneously represent promising future directions. Additionally, ongoing research into the genetic and molecular determinants of IgAN susceptibility and progression may pave the way for personalized treatment approaches, further revolutionizing the management of this chronic kidney disease and enhancing long-term patient outcomes across the global IgAN landscape.

Table of Contents

1. Key Insights

2. Report Introduction

3. IgAN Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Methodology

8. IgAN Epidemiology and Patient Population

9. IgAN Patient Journey

10. IgAN Marketed Drugs

11. IgAN Emerging Drugs

12. IgAN - 7MM Market Analysis

13. KOL Views

14. IgAN Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=iga-nephropathy-therapeutic-market-expected-to-witness-robust-growth-by-2034-fueled-by-recent-fda-approvals-and-clinical-trials-updates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.